Boothbay Fund Management LLC purchased a new position in shares of Inhibrx, Inc. (NASDAQ:INBX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 28,230 shares of the company's stock, valued at approximately $435,000. Boothbay Fund Management LLC owned about 0.19% of Inhibrx as of its most recent SEC filing.
Other institutional investors have also recently added to or reduced their stakes in the company. HighTower Advisors LLC purchased a new position in shares of Inhibrx in the 4th quarter valued at approximately $12,039,000. Walleye Capital LLC purchased a new position in Inhibrx in the 4th quarter valued at $8,932,000. Slotnik Capital LLC purchased a new position in Inhibrx in the 4th quarter valued at $5,975,000. Geode Capital Management LLC acquired a new position in Inhibrx in the 4th quarter valued at $3,930,000. Finally, Kennedy Capital Management LLC purchased a new position in Inhibrx during the 4th quarter worth $2,551,000. Institutional investors and hedge funds own 82.46% of the company's stock.
Wall Street Analyst Weigh In
Separately, JMP Securities reiterated a "market perform" rating on shares of Inhibrx in a research note on Wednesday, January 22nd.
Check Out Our Latest Report on Inhibrx
Inhibrx Stock Performance
Shares of INBX stock traded up $0.18 during trading hours on Monday, reaching $12.33. 179,402 shares of the company's stock were exchanged, compared to its average volume of 193,808. The company's 50 day moving average is $12.97 and its two-hundred day moving average is $13.93. Inhibrx, Inc. has a 1 year low of $10.80 and a 1 year high of $34.75.
Inhibrx (NASDAQ:INBX - Get Free Report) last released its quarterly earnings data on Monday, March 17th. The company reported ($3.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The business had revenue of $0.10 million during the quarter. On average, equities analysts forecast that Inhibrx, Inc. will post 104.88 EPS for the current year.
Inhibrx Company Profile
(
Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Read More
Before you consider Inhibrx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.
While Inhibrx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
